neuro-primary-mental-health-2017-keynote

2 / 8

Page 14
Notes:
J Neurol Neurorehabil Res 2017 | Volume 2 Issue 3
allied
academies
17th International Conference on 4 th International Conference on
NEUROLOGY AND NEUROSCIENCE & MENTAL HEALTH AND PRIMARY CARE
October 16-18, 2017 | Toronto, Canada
Meningiomas represent the most common primary tumors
of the central nervous system. Meningiomas originate
from the arachnoid tissue and are classified into grades I to
III according to the WHO system, with grade III is malignant.
The proliferation rate in meningioma increases from grades
I to III. The majority of clinically encountered meningiomas is
benign, and corresponds to grade I. These tumors have a slow
growth rate and generally are with minimal risk. Since most of
our knowledge about tumors are based on malignant tumors,
thus investigating and comparing elements of transcriptional
expression profiles in these slow growing non-malignant
tumors with those of malignant tumors would help clarify
tumorigenesis and growth, as well as revealing the presence of
molecular elements that must be expressing and are preventing
non-malignant tumors from progressing to malignancy. With
a focus on the profiling of micro RNAs and putative mRNA
targets, deep sequencing of small RNA libraries from two
human meningioma biopsies grades I and II were compared to
excess dura controls. Validation of the differentially expressed
microRNAs and putative mRNA targets in more patient tumors
and controls was by RT-qPCR. The tumor suppressors’ miR-
143, miR-193b and miR-451 were lower in the tumors than the
control. Surprisingly, microRNAs, miR-34a and miR-218 were at
a higher level in tumors than controls. Cancer-promoting miR-
21 RNA was expressed to a much lower level. Observed over-
expressionof p63 and cyclinD1were alsoobserved in cancerous
tumors, while tumor suppressors PTEN and E-cadherin were at
high level. In conclusion, non-cancerous meningiomas share
important biomarkers with cancerous tumors, at least miRNAs
promoting the formation of tumors. However, these non-
malignant tumors also express other biomarkers preventing
progression to cancer. Expanding this study and including other
benign and non-malignant tumors should be investigated.
Speaker Biography
M Raafat El-Gewely currently is Professor Emeritus, Institute of Medical Biology,
University of Tromsø, Norway. He served as Professor of Biotechnology, 1988-2012
(Appointed by king Olav of Norway); Director of Biotechnology Center, University of
Tromsø 1989-1999, Assoc. Research Scientist, Department of Biological Chemistry,
U. of Michigan Medical School. Ann Arbor, Michigan1983-1988; Visiting Scholar at
Dept. of Cellular and Molecular Biology, University of Michigan, 1977-1983. He also
served as Visiting or Adjunct Professor at several universities including UCSD Med
School, Institute for Systems Biology (ISB), Adjunct Professor at Dept. of Biotechnology,
University of Aalborg, Denmark, Dept. of Microbiology and Immunology, Medical
School, University of Michigan; Dept. of Biological Chemistry, Medical School,
University of Michigan, Chief Editor of “Biotechnology Annual Review” (1995- 2009).
He has extensive research experience in in Molecular Biology, Recombinant DNA and
Genetic & Protein Engineering Technologies with numerous publications; developing
therapeutics using a novel alternative approach to gene therapy and genetic control
of protein folding (patents). He is focused on the utilizations of modern tools in
translational applications in medicine.
e:
M Raafat El-Gewely
UiT-The Arctic University of Norway, Norway
Lessons learned from the study of non-malignant meningioma tumors profiling